Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction

Patent metadata

Field	Value
Publication number	US-11878159-B2
Application number	US-202117327926-A
Country	US
Kind code	B2
Filing date	May 24, 2021
Priority date	Dec 7, 2011
Publication date	Jan 23, 2024
Grant date	Jan 23, 2024

Abstract

An implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction is provided. A stimulation therapy lead includes helical electrodes configured to conform to an outer diameter of a cervical vagus nerve sheath, and a set of connector pins electrically connected to the helical electrodes. A neurostimulator includes an electrical receptacle into which the connector pins are securely and electrically coupled. The neurostimulator also includes a pulse generator configured to therapeutically stimulate the vagus nerve through the helical electrodes in alternating cycles of stimuli application and stimuli inhibition that are tuned to both efferently activate the heart's intrinsic nervous system and afferently activate the patient's central reflexes by triggering bi-directional action potentials.

First claim

What is claimed is:

1. A vagus nerve stimulator for treating chronic cardiac dysfunction, comprising:
an implantable neurostimulator comprising:
a pair of helical electrodes;
a nerve stimulation therapy lead electrically coupled to the pair of helical electrodes;
a pulse generator configured to deliver electrical therapeutic stimulation comprising a stimulation waveform applied to both of the helical electrodes via the nerve stimulation therapy lead; and
a recordable memory configured to store stimulation parameters comprising a programmable ON-time during which the pulse generator delivers the electrical therapeutic stimulation, a programmable OFF-time during which the electrical therapeutic stimulation is inhibited, and a periodic duty cycle comprising a percentage calculated from a ratio of the ON-time to the OFF-time;
wherein the periodic duty cycle is within a duty range selected based on a targeted therapeutic efficacy and an extent of potential side effects; and
wherein the pulse generator is further configured to operate under the stimulation parameters stored in the recordable memory.

2. The vagus nerve stimulator of claim 1 , further comprising an integrated heart rate sensor configured to sense a heart rate response to the electrical therapeutic stimulation.

3. The vagus nerve stimulator of claim 1 , wherein the targeted therapeutic efficacy is quantified by assigning values to at least one of acute factors or chronic factors that contribute to a physiological response of a patient due to the delivery of the electrical therapeutic stimulation.

4. The vagus nerve stimulator of claim 3 , wherein the targeted therapeutic efficacy is quantified by assigning values to acute factors including at least one of an increase in heart rate variability, an increase in coronary flow, a reduction in cardiac workload through vasodilation, or left ventricular relaxation.

5. The vagus nerve stimulator of claim 3 , wherein the targeted therapeutic efficacy is quantified by assigning values to chronic factors including at least one of a decreased parasympathetic activation, an increased sympathetic activation, a decreased negative cytokine production, an increased baroreflex sensitivity, an increased respiratory gas exchange efficiency, a favorable gene expression, a renin-angiotensin-aldosterone system down-regulation, or anti-arrhythmic, anti-apoptotic, and ectopy-reducing anti-inflammatory effects.

6. The vagus nerve stimulator of claim 1 , wherein the extent of potential side effects is quantified by assigning values to physiological effects presented due to the delivery of the electrical therapeutic stimulation.

7. The vagus nerve stimulator of claim 6 , wherein the physiological effects include at least one of infection, asystole, bradycardia, syncope, abnormal thinking, aspiration pneumonia, device site reaction, acute renal failure, nerve paralysis, hypesthesia, facial paresis, vocal cord paralysis, facial paralysis, hemidiaphragm paralysis, recurrent laryngeal injury, urinary retention, low grade fever, voice alteration, increased coughing, pharyngitis, paresthesia, dyspnea, dyspepsia, nausea, or laryngismus.

8. The vagus nerve stimulator of claim 1 , wherein the duty range is between 5% and 30%.

9. A method for treating chronic cardiac dysfunction, comprising:
storing, by a recordable memory of a vagus nerve stimulator, stimulation parameters comprising a programmable ON-time during which a pulse generator of the vagus nerve stimulator delivers electrical therapeutic stimulation, a programmable OFF-time during which the electrical therapeutic stimulation is inhibited, and a periodic duty cycle comprising a percentage calculated from a ratio of the ON-time to the OFF-time, wherein the periodic duty cycle is within a duty range selected based on a targeted therapeutic efficacy and an extent of potential side effects; and
operating the pulse generator based on the stimulation parameters to deliver the electrical therapeutic stimulation comprising a stimulation waveform, via a nerve stimulation therapy lead, to helical electrodes electrically coupled to the nerve stimulation therapy lead.

10. The method of claim 9 , further comprising sensing a heart rate response to the electrical therapeutic stimulation using an integrated heart rate sensor of the pulse generator.

11. The method of claim 9 , further comprising quantifying the targeted therapeutic efficacy by assigning values to at least one of acute factors or chronic factors that contribute to a physiological response of a patient due to the delivery of the electrical therapeutic stimulation.

12. The method of claim 11 , wherein the targeted therapeutic efficacy is quantified by assigning values to acute factors including at least one of an increase in heart rate variability, an increase in coronary flow, a reduction in cardiac workload through vasodilation, or left ventricular relaxation.

13. The method of claim 11 , wherein the targeted therapeutic efficacy is quantified by assigning values to chronic factors including at least one of a decreased parasympathetic activation, an increased sympathetic activation, a decreased negative cytokine production, an increased baroreflex sensitivity, an increased respiratory gas exchange efficiency, a favorable gene expression, a renin-angiotensin-aldosterone system down-regulation, or anti-arrhythmic, anti-apoptotic, and ectopy-reducing anti-inflammatory effects.

14. The method of claim 9 , further comprising quantifying the extent of potential side effects by assigning values to physiological effects presented due to the delivery of the electrical therapeutic stimulation.

15. The method of claim 14 , wherein the physiological effects include at least one of infection, asystole, bradycardia, syncope, abnormal thinking, aspiration pneumonia, device site reaction, acute renal failure, nerve paralysis, hypesthesia, facial paresis, vocal cord paralysis, facial paralysis, hemidiaphragm paralysis, recurrent laryngeal injury, urinary retention, low grade fever, voice alteration, increased coughing, pharyngitis, paresthesia, dyspnea, dyspepsia, nausea, or laryngismus.

16. The method of claim 9 , wherein the duty range is between 5% and 30%.

17. An implantable device for treating chronic cardiac dysfunction, comprising:
an implantable neurostimulator comprising a pulse generator configured to deliver electrical therapeutic stimulation in alternating cycles of stimuli application and stimuli inhibition;
a cervical vagus nerve stimulation therapy lead electrically coupled to the pulse generator and terminated by a pair of helical electrodes through which therapeutic stimulation is delivered to a patient's cervical vagus nerve; and
a recordable memory configured to store stimulation parameters configured to define a periodic duty cycle for the alternating cycles of stimuli application and stimuli inhibition, the stimulation parameters comprising a programmable ON-time for the stimuli application and a programmable OFF-time for the stimuli inhibition;
wherein the periodic duty cycle is within a duty range selected based on a targeted therapeutic efficacy and an extent of potential side effects; and
wherein the pulse generator is further configured to operate under the stimulation parameters stored in the recordable memory.

18. The implantable device of claim 17 , further comprising an integrated heart rate sensor configured to sense a heart rate response to the electrical therapeutic stimulation.

19. The implantable device of claim 17 , wherein the targeted

Assignees

• Livanova Usa Inc

Inventors

• Libbus Imad
• Amurthur Badri
• Kenknight Bruce H

Classifications

• A61N1/0556 Primary

  Cuff electrodes · CPC title

• A61N1/36053

  adapted for vagal stimulation (A61N1/36114 takes precedence) · CPC title

• A61N1/36114

  Cardiac control, e.g. by vagal stimulation (stimulating the heart A61N1/362) · CPC title

• A61N1/36175

  Pulse width or duty cycle · CPC title

• A61N1/36057

  adapted for stimulating afferent nerves · CPC title